Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | AHCY | P23526 | 16/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150492 | 0.87 | AHCY (0.77) | ADORA3AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL14304652 | 0.87 | AHCY (0.77) | ADORA3AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL4150498 | 0.87 | AHCY (0.77) | ADORA3AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL21782399 | 0.84 | ADORA3 (0.69) | ADORA3AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL13396560 | 0.84 | ADORA3 (0.60) | ADORA3AHCYHIF1A | |
| SCHEMBL2550330 | 0.81 | ADORA3 (0.75) | ADORA3HIF1AADORA2B | |
| SCHEMBL23050294 | 0.81 | ADORA3 (0.75) | ADORA3HIF1AADORA2B | |
| SCHEMBL21344303 | 0.81 | ADORA3 (0.65) | ADORA3AHCYADORA2B | |
| SCHEMBL12746919 | 0.81 | ADORA3 (0.75) | ADORA3HIF1AADORA2B | |
| SCHEMBL24538798 | 0.81 | ADORA3 (0.75) | ADORA3HIF1AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | ADORA3 1372/4885AHCY 532/4885HIF1A 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.